• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

2.370 -0.050 (-2.07%)
Streaming Delayed Price Updated: 11:06 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 139,888
Open 2.410
Bid (Size) 2.360 (400)
Ask (Size) 2.370 (200)
Prev. Close 2.420
Today's Range 2.360 - 2.480
52wk Range 0.4603 - 7.130
Shares Outstanding 61,540,231
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Corp (NASDAQ:PROK) Reports Q3 2025 Earnings and Clinical Progress ↗
November 10, 2025
ProKidney (PROK) reports Q3 2025 results, beating EPS estimates. Key updates include strong Phase 3 trial enrollment and a confirmed FDA accelerated approval pathway for its kidney disease therapy. 
Via Chartmill

Performance

YTD
+6.3%
+6.3%
1 Month
+0.9%
+0.9%
3 Month
-27.3%
-27.3%
6 Month
-45.4%
-45.4%
1 Year
+29.5%
+29.5%

More News

Read More
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
November 10, 2025
Via MarketMinute
News headline image
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
November 10, 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
November 06, 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
October 29, 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
October 20, 2025
From ProKidney
Via GlobeNewswire
News headline image
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC ↗
October 02, 2025
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
September 12, 2025
Via Chartmill
News headline image
What's going on in today's session ↗
September 11, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
September 11, 2025
Via Benzinga
News headline image
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
August 27, 2025
From ProKidney
Via GlobeNewswire
News headline image
Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid ↗
August 24, 2025
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% ↗
August 19, 2025
Via Benzinga
News headline image
ProKidney Reports 78 Percent Gain in Q2 ↗
August 12, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss ↗
August 12, 2025
Via Chartmill
News headline image
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
August 12, 2025
From ProKidney
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Rocketed 775% Higher ↗
July 22, 2025
Via The Motley Fool
News headline image
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? ↗
July 17, 2025
Via The Motley Fool
News headline image
Unusual volume stocks are being observed in Tuesday's session. ↗
July 15, 2025
Via Chartmill
News headline image
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
July 15, 2025
Via Benzinga
News headline image
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
July 15, 2025
From ProKidney
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
July 14, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
July 10, 2025
Via Benzinga
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
July 10, 2025
Via Chartmill

Frequently Asked Questions

Is ProKidney Corp. - Class A Ordinary Shares publicly traded?
Yes, ProKidney Corp. - Class A Ordinary Shares is publicly traded.
What exchange does ProKidney Corp. - Class A Ordinary Shares trade on?
ProKidney Corp. - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProKidney Corp. - Class A Ordinary Shares?
The ticker symbol for ProKidney Corp. - Class A Ordinary Shares is PROK on the Nasdaq Stock Market
What is the current price of ProKidney Corp. - Class A Ordinary Shares?
The current price of ProKidney Corp. - Class A Ordinary Shares is 2.370
When was ProKidney Corp. - Class A Ordinary Shares last traded?
The last trade of ProKidney Corp. - Class A Ordinary Shares was at 01/08/26 11:06 AM ET
What is the market capitalization of ProKidney Corp. - Class A Ordinary Shares?
The market capitalization of ProKidney Corp. - Class A Ordinary Shares is 145.85M
How many shares of ProKidney Corp. - Class A Ordinary Shares are outstanding?
ProKidney Corp. - Class A Ordinary Shares has 146M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap